2022
Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model
Brennan W, Belser A. Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model. Frontiers In Psychology 2022, 13: 866018. PMID: 35719571, PMCID: PMC9201428, DOI: 10.3389/fpsyg.2022.866018.Peer-Reviewed Original ResearchClinical trialsEvidence-based therapiesPsychedelic-Assisted PsychotherapyPsychiatric indicationsPAP treatmentTreatment outcomesTherapeutic benefitDrug AdministrationPsychedelic treatmentSupportive psychotherapyTherapeutic interventionsStudy therapistsPsychedelic medicineTreatmentTherapist interventionsCurrent standardClinical domainsClinical orientationTherapist trainingTrialsTherapeutic changeResearch standardizationTherapy modelInterventionCurrent article briefly
2018
Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy
Malone TC, Mennenga SE, Guss J, Podrebarac SK, Owens LT, Bossis AP, Belser AB, Agin-Liebes G, Bogenschutz MP, Ross S. Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. Frontiers In Pharmacology 2018, 9: 256. PMID: 29666578, PMCID: PMC5891594, DOI: 10.3389/fphar.2018.00256.Peer-Reviewed Original ResearchCancer-related anxietyPsilocybin-assisted psychotherapyCancer patientsAnti-depressant effectsUnique clinical courseBetter medical outcomesQuality of lifeEffects of psilocybinClinical courseBody of evidenceHastened deathClinician notesMedical outcomesPatientsCancer diagnosisDepressionImproved qualityAcceptance of deathTrialsPsilocybinDeathAnxietyTreatmentPsychotherapyPast trauma
2016
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Journal Of Psychopharmacology 2016, 30: 1165-1180. PMID: 27909164, PMCID: PMC5367551, DOI: 10.1177/0269881116675512.Peer-Reviewed Original ResearchConceptsAnti-depressant effectsCancer-related anxietyQuality of lifeCancer-related psychological distressLife-threatening cancerPrimary outcomeCrossover trialTherapeutic effectPsilocybin treatmentSustained benefitMedical outcomesSymptom reductionSignificant anxietyExistential distressPatientsPsychological distressDepressionSpiritual wellbeingCancerAnxietyPsilocybinTrialsOutcomesTreatmentDistress